NCT07092514 2026-03-17
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
Phase 2 Recruiting
Clinical Trials
13 trialsNCT04927416 2026-03-13
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06007924 2026-02-19
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06961084 2026-01-07
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT06458036 2025-11-25
RAISE
Children's Hospital of Philadelphia
Phase 2 Recruiting
NCT06959511 2025-11-19
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07235566 2025-11-19
MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC
Fudan University
Phase 2 Recruiting
NCT05783323 2025-11-14
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Children's Hospital of Philadelphia
Phase 2 Recruiting
NCT06923826 2025-07-25
TROP2
National University Hospital, Singapore
Phase 2 Recruiting
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT06787911 2025-01-22
Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
Fudan University
Phase 2 Recruiting
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT06087068 2023-10-17
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting